Get regular updates to your inbox.
When added to standard of care, both the experimental oral therapy AMX0035 and the U.S.-approved Radicava ORS oral suspension provide comparable or greater benefits to amyotrophic lateral sclerosis (ALS) patients than standard care alone. However, they won’t be cost-effective if priced like Radicava (edaravone), an approved, into-the-vein ALS…
The Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database, the largest collection of de-identified records on amyotrophic lateral sclerosis (ALS) patients in clinical trials, has been updated with records of participants in three Cytokinetics-sponsored studies. Newly added findings derive from a decade of trials involving nearly 600 ALS patients. Those…
As part of its Tribute Awards, the Muscular Dystrophy Association (MDA) will honor Alan Pestronk, MD, co-director of the MDA & ALS Care Center at Washington University School of Medicine. The Tribute Awards recognizes those “who have been tireless in their efforts” to support members of the neuromuscular disease…
NeuroSense Therapeutics has joined EverythingALS’s open innovation consortium to accelerate the development of treatments for amyotrophic lateral sclerosis (ALS). NeuroSense will provide financial support for ongoing research projects from the patient-focused nonprofit organization, such as those that seek to identify biological and digital biomarkers to help detect and monitor ALS.
NeuroSense Therapeutics and NeuraLight are collaborating to identify digital biomarkers, particularly those drawn from facial videos, that would help in detecting and monitoring amyotrophic lateral sclerosis (ALS) and other neurological diseases. Called occulometric biomarkers, they are derived from videos of patients’ faces captured on a webcam and analyzed…
Albrioza, an oral therapy for amyotrophic lateral sclerosis (ALS) still widely known as AMX0035, is now commercially available in Canada, its developer, Amylyx Pharmaceuticals, announced. Its market availability comes about 1.5 months after the therapy was conditionally approved by Health Canada for this neurodegenerative disease. The regulatory decision was based on…
TDP-43 protein abnormalities characteristic of most amyotrophic lateral sclerosis (ALS) cases contribute to the loss of motor neurons mostly by limiting the function of a protein called stathmin-2 (STMN2), a study reported. Results indicate that boosting STMN2 levels may be a useful approach in treating ALS, according to its…
Pasithea Therapeutics has gained access to AU$1 million (about $694,000) to further its research into anti-integrin antibodies as potential treatments for amyotrophic lateral sclerosis (ALS). The non-dilutive funds became available following the company’s acquisition of Alpha-5 Integrin, the preclinical biotech company that originally developed the experimental antibodies for…
Amylyx Pharmaceuticals has partnered with Sunnybrook Research Institute (SRI) to find new therapeutic candidates for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Under terms of the two-year sponsored research agreement, SRI will work to identify potential therapeutics that potently and specifically inhibit Bax and Bak, two proteins…
The U.S. Food and Drug Administration (FDA) has agreed to review an application from Biogen for approval of the company’s experimental therapy tofersen to treat amyotrophic lateral sclerosis (ALS) associated with mutations in the SOD1 gene. The FDA has granted the application accelerated review and a decision…
Get regular updates to your inbox.